Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31337169 | 1.00 | ACHE (0.51) | ACHENAAATSHRLMNAALDH1A1 | |
| SCHEMBL17363992 | 1.00 | ACHE (0.51) | ACHENAAATSHRLMNAALDH1A1 | |
| SCHEMBL3212718 | 1.00 | ACHE (0.51) | ACHENAAATSHRLMNAALDH1A1 | |
| SCHEMBL31294953 | 1.00 | ACHE (0.51) | ACHENAAATSHRLMNAALDH1A1 | |
| SCHEMBL17363987 | 1.00 | ACHE (0.51) | ACHENAAATSHRLMNAALDH1A1 | |
| SCHEMBL18787221 | 1.00 | ACHE (0.51) | ACHENAAATSHRLMNAALDH1A1 | |
| SCHEMBL17363980 | 1.00 | ACHE (0.51) | ACHENAAATSHRLMNAALDH1A1 | |
| SCHEMBL31245813 | 1.00 | ACHE (0.51) | ACHENAAATSHRLMNAALDH1A1 | |
| SCHEMBL31294975 | 1.00 | ACHE (0.51) | ACHENAAATSHRLMNAALDH1A1 | |
| Cetostearyl Alcohol SCHEMBL28903485 | 1.00 | ACHE (0.51) | ACHENAAATSHRLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387509-A1 | NANOMATERIALS COMPRISING A BIODEGRADABLE FEATURE | BEAM THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4658636-A1 | LIPID COMPOUNDS AND USES THEREOF | Pfizer Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4613741-A2 | LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY | ZIPHIUS NV (BE) | 2025-09-10 | — | — | EP | disclosed |
| EP-4613740-A2 | LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY | ZIPHIUS NV (BE) | 2025-09-10 | — | — | EP | disclosed |
| US-20250275918-A1 | LIPID COMPOSITIONS AND METHODS FOR NUCLEIC ACID DELIVERY | GREENLIGHT BIOSCIENCES INC (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250236599-A1 | LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY | ZIPHIUS NV (BE) | 2025-07-24 | — | — | US | disclosed |
| EP-4426270-B1 | LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY | ZIPHIUS NV (BE) | 2025-07-23 | — | — | EP | disclosed |
| EP-4426271-B1 | LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY | ZIPHIUS NV (BE) | 2025-07-23 | — | — | EP | disclosed |
| EP-4426269-B1 | LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY | ZIPHIUS NV (BE) | 2025-07-16 | — | — | EP | disclosed |
| US-20250188028-A1 | Synthetic Method for Producing Ionizable Amino Lipids | NANOVATION THERAPEUTICS INC. (CA) | 2025-06-12 | — | — | US | disclosed |
| WO-2018107026-A1 | DELIVERY OF TARGET SPECIFIC NUCLEASES | SANGAMO THERAPEUTICS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| EP-3289083-A1 | NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE | The Trustees Of The University Of Pennsylvania (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20170283367-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2017-10-05 | — | — | US | disclosed |
| US-9737619-B2 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | Acuitas Therapeutics, Inc. (CA) | 2017-08-22 | — | — | US | disclosed |
| US-9738593-B2 | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | ACUITAS THERAPEUTICS INC. (CA) | 2017-08-22 | — | — | US | disclosed |
| US-20170157268-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2017-06-08 | — | — | US | disclosed |
| EP-3160938-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics Inc. (CA) | 2017-05-03 | — | — | EP | disclosed |
| WO-2016176330-A1 | NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-11-03 | — | — | WO | disclosed |
| US-20150376115-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC. (CA) | 2015-12-31 | — | — | US | disclosed |
| WO-2015199952-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC. (CA) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283367-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | HNRNPA2B1, RTCB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ACHE 4068/4885NAAA 1331/4885TSHR 657/4885 |
| US-20250275918-A1 | LIPID COMPOSITIONS AND METHODS FOR NUCLEIC ACID DELIVERY | ABHD16A, LIPA, POLRMT | ACHE 4869/4885NAAA 435/4885TSHR 3608/4885 |
| US-20250236599-A1 | LIPID NANOPARTICLES FOR OLIGONUCLEOTIDE DELIVERY | MAPT, NPC1L1, SLC10A1 | ACHE 3913/4885NAAA 3217/4885TSHR 3454/4885 |
| US-20250188028-A1 | Synthetic Method for Producing Ionizable Amino Lipids | FASN, BCAT1, ASNS | ACHE 2809/4885NAAA 170/4885TSHR 2876/4885 |
| US-20250387509-A1 | NANOMATERIALS COMPRISING A BIODEGRADABLE FEATURE | LDLR, TGFBR2, MSR1 | ACHE 2415/4885NAAA 3502/4885TSHR 1564/4885 |
| US-20170157268-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | HNRNPA2B1, RTCB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ACHE 4068/4885NAAA 1331/4885TSHR 657/4885 |
| US-20150376115-A1 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | HNRNPA2B1, RTCB, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ACHE 4068/4885NAAA 1331/4885TSHR 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.